NOVEL INFLAMMATORY RISK MARKERS INCLUDING LPPLA2 AND RISK OF CHD IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)

NOVEL INFLAMMATORY RISK MARKERS INCLUDING LPPLA2 AND RISK OF CHD IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)

Εμφάνιση άλλων εκδόσεων (1)

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Seed, M, Betteridge, J, Caslake, M, Cooper, J, Humphries, S, Neil, A
Μορφή:	Journal article
Έκδοση:	2009

Παρόμοια τεκμήρια

NOVEL INFLAMMATORY RISK MARKERS INCLUDING LPPLA2 AND RISK OF CHD IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)
ανά: Seed, M, κ.ά.
Έκδοση: (2009)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
ανά: Neil, A, κ.ά.
Έκδοση: (2003)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
ανά: Neil, H, κ.ά.
Έκδοση: (2003)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.
ανά: Neil, H, κ.ά.
Έκδοση: (2004)

CURRENT STATIN TREATMENT OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH): RESULTS FROM THE ROYAL COLLEGE OF PHYSICIANS UK NATIONAL AUDIT
ανά: Seed, M, κ.ά.
Έκδοση: (2011)

Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk.
ανά: Humphries, SE, κ.ά.
Έκδοση: (2006)

Elevated lipoprotein(a) levels in Familial Hypercholesterolaemia (FH): prevalence and implications for FH clinical diagnosis
ανά: A. David, κ.ά.
Έκδοση: (2023-12-01)

The utility of DNA-based testing in patients with familial hypercholesterolaemia in the UK
ανά: Humphries, SE, κ.ά.
Έκδοση: (2005)

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study
ανά: Neil, A, κ.ά.
Έκδοση: (2008)

Modelling a two-stage screen for autosomal dominant familial hypercholesterolaemia (FH) in UK Biobank
ανά: J. Gratton, κ.ά.
Έκδοση: (2022-10-01)

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study.
ανά: Neil, A, κ.ά.
Έκδοση: (2008)

IN APPLICABILITY OF THE CARDIOVASCULAR RISK PREDICTOR "SCORE" TO PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA (FH)
ανά: Descamps, O, κ.ά.
Έκδοση: (2010)

How many individuals with Familial Hypercholesterolaemia (FH) need to be identified to achieve the NHS 2019 Long Term Plan ambition?
ανά: S.E. Humphries, κ.ά.
Έκδοση: (2023-12-01)

Statins and familial hypercholesterolaemia.
ανά: Neil, A, κ.ά.
Έκδοση: (2009)

How many homozygous Familial Hypercholesterolaemia (FH) patients are there likely to be in the UK? : The FH phenotype caused by the APOB p.(Arg3527Trp) variant in a South Asian family
ανά: I. Tracey, κ.ά.
Έκδοση: (2022-10-01)

Identification of FH-causing variants in patients with clinical familial hypercholesterolaemia recruited into the 100,000 genome project: preliminary analysis
ανά: A. Rimbert, κ.ά.
Έκδοση: (2021-09-01)

A novel combinatorial non-viral vector to treat familial hypercholesterolaemia (FH)
ανά: Kerr, A, κ.ά.
Έκδοση: (2016)

Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study.
ανά: Neil, H, κ.ά.
Έκδοση: (2003)

Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study.
ανά: Neil, H, κ.ά.
Έκδοση: (2005)

Prevalence of familial hypercholesterolaemia (FH)-causing variants and impact on LDL-C concentration in European, South Asian, and African ancestry groups of the UK Biobank
ανά: J. Gratton, κ.ά.
Έκδοση: (2023-12-01)

More evidence for inflammatory markers in predicting CHD risk
ανά: Lyford Joanna, κ.ά.
Έκδοση: (2001-03-01)

Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia.
ανά: Minhas, R, κ.ά.
Έκδοση: (2009)

Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation
ανά: P Sharma, κ.ά.
Έκδοση: (2012-03-01)

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
ανά: Marks, κ.ά.
Έκδοση: (2000-01-01)

Does socioeconomic status have an effect on the treatment and outcomes of individuals with familial hypercholesterolaemia (FH)? : a cohort study of individuals with FH in UK primary care
ανά: B. Iyen, κ.ά.
Έκδοση: (2021-09-01)

Cardiovascular disease morbidity is associated with social deprivation in subjects with familial hypercholesterolaemia (FH): a study comparing FH individuals in UK primary care and the UK Simon Broome register linked with secondary care records
ανά: B. Iyen, κ.ά.
Έκδοση: (2022-10-01)

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
ανά: Marks, D, κ.ά.
Έκδοση: (2000)

19. Using a novel combinatorial non-viral vector and small molecules to treat familial hypercholesterolaemia (FH)
ανά: Kerr, A, κ.ά.
Έκδοση: (2016)

Children and young adults with familial hypercholesterolaemia (FH) have healthier food choices particularly with respect to dietary fat sources compared with non-FH children
ανά: Ingunn Molven, κ.ά.
Έκδοση: (2013-01-01)

A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia.
ανά: Marks, D, κ.ά.
Έκδοση: (2003)

Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia.
ανά: Marks, D, κ.ά.
Έκδοση: (2002)

Familial hypercholesterolaemia
ανά: D.J. Blom
Έκδοση: (2011-01-01)

Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes.
ανά: Marks, D, κ.ά.
Έκδοση: (2006)

The development of a theory informed behaviour change intervention to improve adherence to dietary and physical activity treatment guidelines in individuals with familial hypercholesterolaemia (FH)
ανά: F. J. Kinnear, κ.ά.
Έκδοση: (2020-01-01)

Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study.
ανά: Neil, H, κ.ά.
Έκδοση: (2000)

Cardiovascular Disease Risk Estimation in Mutation Confirmed Familial Hypercholesterolaemia
ανά: E. Ofagbor, κ.ά.
Έκδοση: (2023-12-01)

Familial hypercholesterolaemia.
ανά: Gill, P, κ.ά.
Έκδοση: (2012)

Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002.
ανά: Neil, H, κ.ά.
Έκδοση: (2004)

Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening.
ανά: Marks, D, κ.ά.
Έκδοση: (2003)

Reduction in cardiovascular disease morbidity of men and women with familial hypercholesterolaemia (FH) associated with availability of high intensity statins: A cohort study using data from the UK Simon Broome Register linked with secondary care records
ανά: B. Iyen, κ.ά.
Έκδοση: (2021-09-01)